Whooping cough;Coqueluche

EMC - Maladies Infectieuses

Volumn 2, Issue 2, 2005, Pages 84-96

  Guiso, N ^a   Bassinet, L ^b  

^a INSTITUT PASTEUR   (France)

^b CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

Adhesins; Subunit vaccines; Toxins; Whole cell vaccines; Whooping cough

Indexed keywords

EID: 32644439900     PISSN: 1638623X     EISSN: 1638623X     Source Type: Journal    
DOI: 10.1016/j.emcmi.2004.11.001     Document Type: Short Survey

References (36)

1. Arico B, Gross R, Smida J, Rappuoli R. Evolutionary relationships in the genus Bordetella. Mol Microbiol 1987;1: 301-8.
2. Baron S, Njamkepo E, Grimprel E, Begue P, Desenclos JC, Drucker J, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J 1998;17:412-8.
3. Bass JW, Zacher LL. Do newborn infants have passive immunity to pertussis? Pediatr Infect Dis J 1989;8:352-3.
4. Bassinet L, Gueirard P, Maitre B, Housset B, Gounon P, Guiso N. Role of adhesins and toxins in invasion of human tracheal epithelial cells by Bordetella pertussis. Infect Immun 2000;68:1934-41.
5. Bordet J, Gengou O. Le microbe de la coqueluche. Ann Inst Pasteur (Paris) 1907;21:720-6.
6. Boursaux-Eude C, Guiso N. Polymorphism of the repeated regions of pertactin in Bordetella pertussis, Bordetella parapertussis and Bordetella bronchispetica. Infect Immun 2000;68:4815-7.
7. Bromberg K, Tannis G, Steiner P. Detection of Bordetella pertussis associated with the alveolar macrophages of children with human immunodeficiency virus infection. Infect Immun 1991;59:4715-9.
8. Caroff M, Karibian D, Cavaillon JM, Haeffner-Cavaillon N. Structural and functional analyses of bacterial lipopolysaccharides. Microbes Infect 2002;4:915-26.
9. Cattaneo LA, Reed GW, Haase DH, Wills MJ, Edwards KM. The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 years. J Infect Dis 1996;173: 1256-9.
10. Cummings CA, Brinig MM, Lepp PW, Van de Pas S, Relman DA. Bordetella species are distinguished by patterns of substantial gene loss and host adaptation. J Bacteriol 2004;186:1484-92.
11. Gaudelus J, Guiso N, Reinert P. Les vaccins coquelucheux: composition, tolérance, immunogénicité et efficacité. Justifications du calendrier vaccinal en France. Méd Mal Infect 2001;31 (suppl1):86-97.
12. Gilberg S, Njamkepo E, Du Chatelet IP, Partouche H, Gueirard P, Ghasarossian C, et al. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a french area with very high whole-cell vaccine coverage. J Infect Dis 2002;186:415-8.
13. Grimprel E, Begue P, Anjak I, Njamkepo E, Francois P, Guiso N. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clin Diagn Lab Immunol 1996;3:93-7.
14. Gueirard P, Druilhe A, Pretolani M, Guiso N. Role of adenylate cyclase-hemolysin in alveolar macrophage apoptosis during Bordetella pertussis infection in vivo. Infect Immun 1998;66:1718-25.
15. Guiso N. Bordetella. In: Freney FR, Ansen W, Bollet C, editors. Actualités permanentes en bactériologie clinique. Paris: AGPA-ESKA; 2002. p. 1-20.
16. Guiso N. Isolation, identification and characterization of Bordetella pertussis. Dev Biol Standard 1997;89:233-8.
17. Guiso N, Grimprel E, Anjak I, Begue P. Western-blot analysis of antibody responses of young infants to pertussis infection. Eur J Clin Microbiol Infect Dis 1993;12:596-600.
18. Kendrick PL, Eldering G, Dixon MK, Misner J. Mouse protection tests in the study of pertussis vaccine. Am J Public Health 1947;37:803-10.
19. Khelef N, Zychlinsky A, Guiso N. Bordetella pertussis induces apoptosis in macrophages: role of adenylate cyclase-hemolysin. Infect Immun 1993;61:4064-71.
20. Kloos WE, Mohapatra N, Dobrogosz WJ, Ezzell JW, Manclark CR. Deoxyribonucleotide sequence relationships among Bordetella species. Int J Syst Bact 1981;31:173-6.
21. Leslie PH, Gardner AD. The phases of Haemophilus pertussis. J Hyg Camb 1931;31:423-34.
22. Mattoo S, Foreman-Wykert AK, Cotter PA, Miller JF. Mechanisms of Bordetella pathogenesis. Front Biosci 2001; 6:1.
23. Mills KH. Immunity to Bordetella pertussis. Microbes Infect 2001;3:655-77.
24. Mooi FR, Hallander H, Wirsing von Köning CH, Hoet B, Guiso N. Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. Eur Clin Infect Dis J 2000;19:174-81.
25. Musser JM, Hewlett EL, Peppler MS, Selander RK. Genetic diversity and relationships in populations of Bordetella spp. J Bacteriol 1986;166:230-7.
26. Njamkepo E, Rimlinger F, Thiberge S, Guiso N. Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine 2002;20:1290-4.
27. Parkhill J, Sebaihia M, Preston A, Murphy LD, Thomson N, Harris DE, et al. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica, Nat Genet 2003;35:32-40.
28. Preston A, Parkhill J, Maskell DJ. The Bordetellae: lessons from genomics. Nat Rev Microbiol 2004;2:379-90.
29. Saukkonen K, Burnette WN, Mar VL, Masure HR, Tuomanen El. Pertussis toxin has eukaryotic-like carbohydrate recognition domains. Proc Natl Acad Sci USA 1992; 89:118-22.
30. Seddon PC, Novotny P, Hart CA, Smith CS. Systemic and mucosal antibody response to Bordetella pertussis antigens in children with whooping cough. Serodiagn Immunother Infect Dis 1989;3:337-43.
31. Simondon F, Preziosi MP, Yam A, Kane CT, Chabirand L, Iteman I, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997;15:1606-12.
32. Standfast AF. The comparison between field trials and mouse protection tests against intranasal and intracerebral challenges with Bordetella pertussis. Immunology 1958;2:135-43.
33. Stockbauer KE, Foreman-Wykert AK, Miller JF. Bordetella type III secretion induces caspase 1-independent necrosis. Cell Microbiol 2003;5:123-32.
34. Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N. Polymorphism of Bordetella pertussis isolates circulating the last ten years in France, where a single effective whole-cell vaccine has been used for more than thirty years. J Clin Microbiol 2001;39:4396-403.
35. Weingart CL, Mobberley-Schuman PS, Hewlett EL, Gray MC, Weiss AA. Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils. Infect Immun 2000;68:7152-5.
36. Wirsing von Konig CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002;2: 744-50.